Instead, we might expose patients for 6 to 12 months. We won’t expose the patients to the long-term toxicity of these drugs. I think, in the future, if some of these drugs come out, probably a more time-limited treatment would be better.
“We use all these novel agents in the same fashion where we continue them until progression or toxicity. This tactic may improve outcomes overall. Khan, a hematologist in the Division of Hematology and Cellular Therapy at West Penn Hospital of Allegheny Health Network, explained that it would be the best interest of investigators to limit the amount of time a patient is on certain drugs, in the future. Regarding prospective agents, there have been continuous reports of positive efficacy in clinical trials of patients with CLL/SLL, but safety has been of concern for some therapies. Khan, MD, the current drug pipeline is also abundant with promising prospects. An array of Bruton’s tyrosine kinase (BTK) inhibitors are available for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
0 kommentar(er)
